NASDAQ:PRAH - PRA Health Sciences Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $107.09
  • Forecasted Upside: -5.91 %
  • Number of Analysts: 12
  • Breakdown:
  • 1 Sell Ratings
  • 6 Hold Ratings
  • 5 Buy Ratings
  • 0 Strong Buy Ratings
$113.82
▲ +1.62 (1.44%)
1 month | 3 months | 12 months
Get New PRA Health Sciences Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for PRAH and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for PRAH

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$107.09
▼ -5.91% Downside Potential
This price target is based on 12 analysts offering 12 month price targets for PRA Health Sciences in the last 3 months. The average price target is $107.09, with a high forecast of $125.00 and a low forecast of $89.00. The average price target represents a -5.91% upside from the last price of $113.82.
Hold
The current consensus among 12 investment analysts is to hold stock in PRA Health Sciences. This rating has held steady since December 2019, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 6 buy ratings
  • 3 hold ratings
  • 0 sell ratings
6/10/2019
  • 0 strong buy ratings
  • 4 buy ratings
  • 4 hold ratings
  • 0 sell ratings
9/8/2019
  • 0 strong buy ratings
  • 4 buy ratings
  • 4 hold ratings
  • 0 sell ratings
12/7/2019
  • 0 strong buy ratings
  • 3 buy ratings
  • 5 hold ratings
  • 0 sell ratings
3/6/2020
  • 0 strong buy ratings
  • 5 buy ratings
  • 7 hold ratings
  • 0 sell ratings
6/4/2020
  • 0 strong buy ratings
  • 5 buy ratings
  • 6 hold ratings
  • 1 sell ratings
9/2/2020
  • 0 strong buy ratings
  • 5 buy ratings
  • 6 hold ratings
  • 1 sell ratings
11/1/2020
  • 0 strong buy ratings
  • 5 buy ratings
  • 6 hold ratings
  • 1 sell ratings
12/1/2020

Latest Recommendations

  • 0 strong buy ratings
  • 5 buy ratings
  • 6 hold ratings
  • 1 sell ratings

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
11/5/2020Credit Suisse GroupBoost Price TargetOutperform$120.00 ➝ $125.00High
i
8/10/2020UBS GroupBoost Price TargetNeutral$105.00 ➝ $111.00Medium
i
8/10/2020Bank of AmericaDowngradeBuy ➝ Underperform$110.00 ➝ $100.00Low
i
8/10/2020MizuhoBoost Price TargetNeutral ➝ In-Line$92.00 ➝ $108.00Low
i
8/10/2020CitigroupBoost Price TargetNeutral$90.00 ➝ $110.00Low
i
8/7/2020Credit Suisse GroupBoost Price TargetOutperform$113.00 ➝ $116.00Medium
i
5/5/2020UBS GroupLower Price TargetNeutral$103.00 ➝ $101.00Low
i
5/4/2020SunTrust BanksBoost Price TargetBuy$89.00 ➝ $103.00Low
i
5/4/2020Robert W. BairdLower Price TargetOutperform$106.00 ➝ $101.00Medium
i
5/1/2020Credit Suisse GroupLower Price TargetOutperform$122.00 ➝ $113.00High
i
5/1/2020William BlairDowngradeOutperform ➝ Market PerformHigh
i
Rating by J. Kreger at William Blair
4/28/2020UBS GroupLower Price TargetNeutral$116.00 ➝ $103.00Low
i
4/13/2020Wolfe ResearchDowngradeOutperform ➝ Market Perform$97.00Medium
i
Rating by Steve Baxter at Wolfe Research
4/9/2020CitigroupLower Price TargetNeutral$120.00 ➝ $90.00High
i
4/3/2020MizuhoLower Price TargetNeutral$95.00 ➝ $82.00High
i
3/26/2020BarclaysLower Price TargetOverweight$123.00 ➝ $114.00Medium
i
3/23/2020Jefferies Financial GroupLower Price TargetBuy$125.00 ➝ $89.00Low
i
3/17/2020SunTrust BanksLower Price TargetBuy$127.00 ➝ $89.00High
i
2/21/2020Robert W. BairdBoost Price TargetOutperform$122.00 ➝ $128.00High
i
1/10/2020The Goldman Sachs GroupDowngradeBuy ➝ Neutral$130.00 ➝ $120.00High
i
1/6/2020CitigroupInitiated CoverageNeutral$120.00Medium
i
11/14/2019Wolfe ResearchUpgradePeer Perform ➝ Outperform$123.00Medium
i
9/19/2019The Goldman Sachs GroupInitiated CoverageBuy$126.00Low
i
9/6/2019Jefferies Financial GroupBoost Price TargetBuy$115.00 ➝ $120.00Low
i
9/4/2019BarclaysBoost Price TargetOverweight$115.00 ➝ $118.00High
i
7/2/2019SVB LeerinkReiterated RatingMarket PerformMedium
i
Rating by D. Larsen at SVB Leerink LLC
5/3/2019MizuhoSet Price TargetHold$100.00Low
i
Rating by Ann Hynes at Mizuho
4/2/2019Wolfe ResearchInitiated CoverageMarket PerformMedium
i
3/4/2019SunTrust BanksBoost Price TargetBuy ➝ Average$120.00Low
i
2/28/2019Robert W. BairdBoost Price TargetOutperform ➝ Outperform$119.00 ➝ $122.00High
i
11/5/2018SunTrust BanksBoost Price TargetBuy$120.00Medium
i
10/9/2018UBS GroupInitiated CoverageNeutral ➝ NeutralMedium
i
10/4/2018Evercore ISIInitiated CoverageIn-Line ➝ Inline$120.00High
i
9/11/2018Robert W. BairdBoost Price TargetOutperform ➝ Outperform$112.00 ➝ $116.00Low
i
8/6/2018MizuhoSet Price TargetHold$100.00High
i
Rating by Ann Hynes at Mizuho
8/3/2018SunTrust BanksBoost Price TargetAverage ➝ Buy$100.00 ➝ $110.00Low
i
8/2/2018KeyCorpReiterated RatingBuy$115.00Low
i
8/2/2018Credit Suisse GroupBoost Price TargetOutperform ➝ Outperform$104.00 ➝ $107.00Low
i
8/2/2018BarclaysBoost Price TargetOverweight ➝ Overweight$100.00 ➝ $115.00Low
i
7/20/2018Jefferies Financial GroupReiterated RatingBuy$115.00Medium
i
2/22/2018Credit Suisse GroupReiterated RatingOutperform ➝ Outperform$101.00 ➝ $104.00High
i
1/31/2018KeyCorpReiterated RatingBuy$100.00Low
i
1/24/2018MizuhoDowngradeBuy ➝ Neutral$86.00High
i
Rating by Ann Hynes at Mizuho
12/15/2017Mitsubishi UFJ Financial GroupInitiated CoverageOverweight$102.00Low
i
Rating by J. Twizell at Mitsubishi UFJ Financial Group
12/11/2017BarclaysInitiated CoverageOverweight ➝ Overweight$94.00Medium
i
12/1/2017Robert W. BairdSet Price TargetBuy$94.00Low
i
12/1/2017MizuhoSet Price TargetBuy ➝ Buy$82.00 ➝ $87.00Low
i
Rating by Ann Hynes at Mizuho
10/30/2017KeyCorpReiterated RatingBuy$86.00 ➝ $93.00N/A
i
10/27/2017SunTrust BanksReiterated RatingBuy$101.00N/A
i
10/26/2017Credit Suisse GroupBoost Price TargetOutperform$90.00 ➝ $93.00N/A
i
10/26/2017Jefferies Financial GroupReiterated RatingBuy$95.00N/A
i
Rating by Biren Amin at Jefferies Financial Group Inc.
10/16/2017Credit Suisse GroupReiterated RatingOutperform$84.00 ➝ $90.00N/A
i
10/9/2017Robert W. BairdReiterated RatingBuy$88.00N/A
i
9/21/2017MizuhoInitiated CoverageBuy$82.00Low
i
8/16/2017Raymond JamesInitiated CoverageOutperform ➝ Outperform$89.00Low
i
8/10/2017Jefferies Financial GroupReiterated RatingBuy$88.00 ➝ $92.00Low
i
Rating by Biren Amin at Jefferies Financial Group Inc.
8/10/2017CitigroupReiterated RatingBuy$90.00 ➝ $93.00Low
i
8/9/2017SunTrust BanksReiterated RatingBuyHigh
i
8/8/2017Credit Suisse GroupBoost Price TargetOutperform ➝ Outperform$80.00 ➝ $84.00High
i
8/8/2017Robert W. BairdBoost Price TargetOutperform$82.00 ➝ $83.00High
i
6/28/2017CitigroupReiterated RatingBuy$73.00 ➝ $90.00Low
i
6/26/2017Bank of AmericaInitiated CoverageBuy$89.00Low
i
6/6/2017Credit Suisse GroupReiterated RatingOutperform$69.00 ➝ $76.00Low
i
6/1/2017Jefferies Financial GroupSet Price TargetBuy$73.00Low
i
Rating by Biren Amin at Jefferies Financial Group Inc.
4/28/2017Jefferies Financial GroupBoost Price TargetBuy$72.00 ➝ $72.50Low
i
2/27/2017Avondale PartnersUpgradeUnderperform ➝ Market Perform$63.00N/A
i
2/23/2017Jefferies Financial GroupReiterated RatingBuy$66.00N/A
i
2/6/2017Credit Suisse GroupUpgradeNeutral ➝ Outperform$67.00N/A
i
1/24/2017Jefferies Financial GroupBoost Price TargetBuy$63.00 ➝ $66.00N/A
i
1/14/2017Jefferies Financial GroupReiterated RatingBuy$63.00N/A
i
11/4/2016KeyCorpReiterated RatingBuyN/A
i
Rating by Donald Hooker at KeyCorp
11/3/2016Credit Suisse GroupReiterated RatingHold$50.00N/A
i
Rating by Erin Wilson at Credit Suisse Group AG
9/22/2016CitigroupBoost Price TargetBuy$55.00 ➝ $66.00N/A
i
Rating by Garen Sarafian at Citigroup Inc.
9/13/2016Jefferies Financial GroupReiterated RatingBuyN/A
i
9/6/2016UBS GroupDowngradeBuy ➝ Neutral$50.00 ➝ $55.00N/A
i
7/29/2016UBS GroupReiterated RatingBuy$50.00N/A
i
7/29/2016Jefferies Financial GroupReiterated RatingBuy$57.00N/A
i
6/20/2016First AnalysisInitiated CoverageEqual ➝ Equal Weight$47.00N/A
i
6/20/2016Credit Suisse GroupInitiated CoverageNeutral$43.00N/A
i
6/13/2016KeyCorpUpgradeSector Weight ➝ Overweight$55.00N/A
i
Rating by Donald Hooker at KeyCorp
5/22/2016KeyCorpReiterated RatingHoldN/A
i
5/4/2016CitigroupUpgradeNeutral ➝ Buy$51.00 ➝ $53.00N/A
i
3/28/2016SunTrust BanksUpgradeNeutral ➝ Buy$47.00 ➝ $51.00N/A
i
2/26/2016Jefferies Financial GroupBoost Price Target$49.50 ➝ $50.00N/A
i
12/8/2015Jefferies Financial GroupBoost Price TargetBuy$49.50N/A
i
(Data available from 12/1/2015 forward)
PRA Health Sciences logo
PRA Health Sciences, Inc., a contract research organization, provides outsourced clinical development and data solution services to the biotechnology and pharmaceutical industries worldwide. The company operates in two segments, Clinical Research and Data Solutions. The Clinical Research segment offers product registration services, including clinical trial management, project management, regulatory affairs, therapeutic expertise, clinical operations, data and programming, safety and risk management, biostatistics and medical writing, quality assurance, and late phase services. It also provides strategic solutions, such as embedded, functional services provider, staff augmentation, and custom-built development solutions, as well as commercialization services; and early development services for Phase I and Phase IIa studies, as well as bioanalytical analysis. The Data Solutions segment offers data, analytics, technology, and consulting solutions to the life sciences market. Its services include market intelligence services, such as targeting and compensation, and pharmaceutical audit suite services; consulting and services comprising brand analytics, managed markets, commercial effectiveness, and scientific studies/clinical hubs; and technology-enabled products and services that clients to access and analyze Symphony Health and integrated third-party data. PRA Health Sciences, Inc. conducts clinical trials in the areas of pharmaceutical development, including oncology, immunology, central nervous system, inflammation, respiratory, cardiometabolic, and infectious diseases. The company has a partnership with The Leukemia & Lymphoma Society to launch a clinical trial for developing treatments for children with relapsed acute leukemia. The company was formerly known as PRA Global Holdings, Inc. and changed its name to PRA Health Sciences, Inc. in July 2014. PRA Health Sciences, Inc. was founded in 1976 and is headquartered in Raleigh, North Carolina.
Read More

Today's Range

Now: $113.82
$113.08
$115.06

50 Day Range

MA: $108.67
$97.44
$113.67

52 Week Range

Now: $113.82
$58.67
$118.44

Volume

2,331 shs

Average Volume

394,755 shs

Market Capitalization

$7.30 billion

P/E Ratio

34.91

Dividend Yield

N/A

Beta

1.05